On a fundraising roll, Dynavax Technologies Corp. priced a $39. 1 million public stock offering as beleaguered hepatitis B vaccine Heplisav wraps up its final Phase III trials and marches toward a biologics license application filing next year. (BioWorld Today)

The good news is that Pacific Biosciences Inc. raised a hefty $200 million in its initial public offering, pricing at the midpoint of its expected range and closing up on its first day of trading. (BioWorld Today)

Facing limited venture financing and public offering options, many biotechs remain focused on cost control, seeking the fastest and cheapest way to push their products through Phase II trials and obtain those critical proof-of-concept data that seem to make deep-pocketed partners prick up their ears.

MacroGenics Inc. and partner Eli Lilly and Co.'s teplizumab failed to meet its primary efficacy endpoint in a Phase III trial for Type 1 diabetes. (BioWorld Today)

Obesity's "big three" are top of mind these days, thanks to recent FDA panel rejections and upcoming FDA decision dates for Arena Pharmaceuticals Inc.'s Lorqess (lorcaserin) and Vivus Inc.'s Qnexa (phentermine/topiramate), as well as a pending panel for Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR).